Please see the below release from Avrobio.
Interested in participating? AVRO-RD-01-201 is a Phase2, open-label multinational clinical trial designed to evaluate the safety and efficacy of AVR-RD-01, an ex vivo, lentiviral vector-mediated gene therapy in individuals with Fabry disease.
Eligibility criteria:
The AVRO trial is being conducted around the world and in sites in Canada. If you are interested in participating please send us a message at the Canadian Fabry Association or reach out directly to Dr. Aneal Khan at the Children’s Alberta Hospital at : aneal.khan@ahs.ca or Shelly Jelinski at Shelly.Jelinski@albertahealthservices.ca for more information. Please call Shelly at 403-955-7874
Study information website: https://avrobiofabrytrial.com/
Subscribe error, please review your email address.
CloseYou're now subscribed, thank you!
CloseThere was a problem with your submission. Please check the field(s) with red label below.
CloseYour message has been sent. We'll get back to you soon!
Close